Abstract 10770: Effects of Glucagon-Like Peptide-1 Receptor Agonists on Patients With or Without Heart Failure: A Meta-Analysis of Randomized Control Trials

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP -1RAs) reduce the risk of a major adverse cardiovascular event (MACE) and heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, these outcomes are not similarly demonstrated in those with HF in subgroup analyses of several randomized controlled trials (RCTs). We evaluated the effect of GLP-1RAs on MACE and HF admissions for T2DM patients with the previous history of HF. Methods: We searched PubMed and EMBASE through March 2022 to identify RCTs examining the effects of GLP-1RAs compared to placebo on MACE and HF admission in T2DM patients with a history of HF. MACE was mainly defined as a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke. We performed a meta-analysis with random effects model. Results: Our analysis included subgroup analyses of 7 RCTs enrolling a total of 8,965 patients with T2DM and history of HF. Pooled analysis demonstrated a significant decreased MACE (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.78-0.99; P = 0.039; I2 = 18.1%) in the GLP-1RAs group (Figure 1A). In contrast, the rate of HF admission was not significantly different between the both groups (HR, 1.03; 95% CI, 0.91-1.16; P = 0.67; I2 = 0.0%) (Figure 1B). Conclusions: GLP-1RAs significantly reduced MACE in patients with HF and T2DM compared to the placebo group but did not affect the risk of HF admission in both groups.